TRANSDERMAL ABSORPTION PREPARATION
    2.
    发明公开
    TRANSDERMAL ABSORPTION PREPARATION 审中-公开
    TRANSDERMALESABSORPTIONSPRÄPARAT

    公开(公告)号:EP1652523A4

    公开(公告)日:2008-11-19

    申请号:EP04748201

    申请日:2004-08-03

    摘要: [PROBLEMS] To provide a transdermal absorption preparation with little skin irritation whereby 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197), which is scarcely absorbed via the skin and has antagonism to bladder-selective muscarine receptors M3 and M1, can be continuously and efficiently absorbed into the body via the skin so that a sustained efficacy can be obtained while showing little side effects. [MEANS FOR SOLVING PROBLEMS] A transdermal absorption preparation is formed by flattening, drying or accumulating a composition comprising KRP-197 and an external preparation base to give a transdermal absorption preparation of the pressure-sensitive single layer type or a transdermal absorption preparation of the reservoir type. Thus, a preparation being excellent in the skin permeation of KRP-197 and sustained absorption thereof into the body and showing little skin irritation can be provided.

    摘要翻译: 本发明提供一种皮肤刺激性小的透皮吸收制剂,其几乎不通过皮肤吸收并且对膀胱刺激具有拮抗作用的4-(2-甲基-1-咪唑基)-2,2-二苯基丁酰胺(KRP-197) 选择性毒蕈碱受体M3和M1可以通过皮肤连续和有效地吸收到体内,从而获得持续的功效,同时显示出很小的副作用。 [解决问题的方法]透皮吸收制剂是通过将含有KRP-197和外用剂基剂的组合物压平,干燥或积聚而制成压敏性单层型的经皮吸收制剂或其制剂的透皮吸收制剂 水库类型。 因此,可以提供KRP-197的皮肤渗透性优异并且持续吸收到体内并且几乎不显示皮肤刺激性的制剂。